1. Home
  2. FNLC vs LUNG Comparison

FNLC vs LUNG Comparison

Compare FNLC & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Bancorp Inc  (ME)

FNLC

First Bancorp Inc (ME)

N/A

Current Price

$33.50

Market Cap

392.2M

Sector

Finance

ML Signal

N/A

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

N/A

Current Price

$1.92

Market Cap

97.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FNLC
LUNG
Founded
1864
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Industrial Specialties
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
392.2M
97.1M
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
FNLC
LUNG
Price
$33.50
$1.92
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
★ $3.40
AVG Volume (30 Days)
26.7K
★ 255.6K
Earning Date
10-21-2026
10-28-2026
Dividend Yield
★ 4.56%
N/A
EPS Growth
★ 26.34
7.64
EPS
★ 1.65
N/A
Revenue
N/A
★ $90,497,000.00
Revenue This Year
N/A
$0.06
Revenue Next Year
N/A
$8.58
P/E Ratio
$20.48
★ N/A
Revenue Growth
N/A
★ 8.01
52 Week Low
$24.13
$1.13
52 Week High
$36.30
$2.89

Technical Indicators

Market Signals
Indicator
FNLC
LUNG
Relative Strength Index (RSI) 34.48 44.84
Support Level $32.73 $1.20
Resistance Level $36.02 $2.12
Average True Range (ATR) 0.87 0.10
MACD -0.19 -0.01
Stochastic Oscillator 6.79 36.65

Price Performance

Historical Comparison
FNLC
LUNG

About FNLC First Bancorp Inc (ME)

First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services, including deposit accounts and consumer, commercial, and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: